Trial Profile
A trial of temozolomide and pasireotide for the treatment of patients with aggressive pituitary adenoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2016
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Temozolomide (Primary)
- Indications Pituitary adenoma
- Focus Therapeutic Use
- 04 Feb 2016 New trial record